-
2024-514022-23-00
4
2023-06-23
Early breast cancer
-
2022-501808-96-00
4
2023-05-15
Mantle Cell Lymphoma
-
2023-506716-41-00
9
2023-05-08
Adult patients with advanced (metastatic or unresectable) KRAS G12C
mu
-
2022-501187-18-00
5
2023-04-24
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
-
2024-511219-78-00
5
2023-02-28
epithelial ovarian cancer
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2024-514139-50-00
5
2022-11-14
Multiple myeloma
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2023-508425-28-00
4
2022-10-24
Chronic Inflammatory Demyelinating Polyneuropathy
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2023-507461-26-00
5
2022-09-22
Newly diagnosed acute myeloid leukemia (AML)
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2023-507699-38-00
5
2022-08-30
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-509278-41-00
5
2022-07-04
Early Stage Follicular LymphOma
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-505347-38-00
9
2022-06-13
B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
-
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
-
2023-503651-10-00
7
2022-05-17
Male and female participants ≥ 18 years of age with advanced or
metast
-
2023-504599-10-00
4
2022-03-29
Chronic lymphocytic leukemia recurrent
-
2023-508881-14-00
9
2022-03-21
Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic sy
-
2023-504152-97-00
5
2021-11-26
Generalized Myasthenia Gravis
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre